INTS

3.80

2.31% -0.09

Handel nachbörslich: 3.80

Intensity Therapeutics Inc (INTS)

Überblick Nachrichten Preisverlauf Financials Warum fällt INTS? Forum Prognose

Schlusskurs vom Vortag:

$3.89

Offen:

$4.0962

24-Stunden-Volumen:

8,434

Relative Volume:

0.23

Marktkapitalisierung:

$12.41M

Einnahmen:

Nettoeinkommen (Verlust:

$-10.69M

KGV:

-0.5366

EPS:

-7.0818

Netto-Cashflow:

$-9.07M

1W Leistung:

-7.54%

1M Leistung:

-22.37%

6M Leistung:

-40.44%

1J Leistung:

-38.71%

1-Tages-Spanne:

$3.80

$4.0962

1-Wochen-Bereich:

$3.80

$4.30

52-Wochen-Spanne:

$3.51

$43.50

Intensity Therapeutics Inc Stock (INTS) Company Profile

Firmenname

Intensity Therapeutics Inc

Sektor

Healthcare (1067)

Branche

Biotechnology (595)

Telefon

203-221-7381

Adresse

1 ENTERPRISE DRIVE, SUITE 430, SHELTON

Mitarbeiter

Twitter

Nächster Verdiensttermin

2026-11-05

Neueste SEC-Einreichungen

INTS's Discussions on Twitter

Compare INTS vs VRTX, REGN, MRNA, ARGX, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
INTS Intensity Therapeutics Inc	3.80	12.41M	0	-10.69M	-9.07M	-7.0818
VRTX Vertex Pharmaceuticals Inc	526.19	133.37B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	788.04	81.13B	14.92B	4.42B	3.79B	41.04
MRNA Moderna Inc	198.88	79.40B	2.23B	-3.19B	-1.60B	-8.1462
ARGX Argen X Se Adr	959.49	60.03B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	204.97	43.93B	742.00K	-1.37B	-1.07B	-7.0731

Intensity Therapeutics Inc Aktie (INTS) Neueste Nachrichten

Sep 21, 2026

symbol__ Stock Quote Price and Forecast - CNN

Sep 21, 2026

Sep 19, 2026

Analysts Are Bullish on Top Healthcare Stocks: Corcept Therapeutics (CORT), Xenon (XENE) - The Globe and Mail

Sep 19, 2026

Sep 11, 2026

Intensity Therapeutics at H.C. Wainwright conference: data, cash and catalysts - Investing.com

Sep 11, 2026

Intensity Therapeutics at H.C. Wainwright conference: data, cash and catalysts By Investing.com - Investing.com Canada

Sep 11, 2026

Sep 08, 2026

Intensity Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - PR Newswire

Sep 08, 2026

Sep 06, 2026

Why Did INTS Stock Plummet 25% Today? - Stocktwits

Sep 06, 2026

Sep 02, 2026

All You Need to Know About Actuate Therapeutics, Inc. (ACTU) Rating Upgrade to Buy - Yahoo Finance

Sep 02, 2026

Aug 26, 2026

12 Health Care Stocks Moving In Wednesday's After-Market Session - Sahm

Aug 26, 2026

Aug 24, 2026

Intensity (INTS) Quarterly Scorecard: EPS Comes in Above Forecast in the Latest Reading; Shares Close 0.41% Lower at the CloseForward EPS Estimate - vinanet.vn

Aug 24, 2026

Aug 23, 2026

Intensity (INTS) Snapshot: Moves 0.41% Down to $4.86; Immediate View: the Current Price Sits Inside the Supplied Technical Range on the DayLate Stage Breakouts - vinanet.vn

Aug 23, 2026

Intensity (INTS) Quarterly Results: Profit Per Share Clears Its Benchmark; Closing Reaction: Shares Move 0.41% LowerEarnings Call Q&A - careplusvn.com

Aug 23, 2026

Aug 22, 2026

Intensity (INTS) Move: Ends Lower by 0.41% at $4.86 in the Current Update; Technical View: Support at $4.62 and Resistance at $5.10 Frame the Range on the DayTechnical Analysis Picks - dars.gov.et

Aug 22, 2026

Aug 19, 2026

Intensity (INTS) Results Review: EPS Comes in Above Forecast in the Current Update - vinanet.vn

Aug 19, 2026

H.C. Wainwright Maintains Intensity Therapeutics(INTS.US) With Buy Rating, Maintains Target Price $7 - Moomoo

Aug 19, 2026

H.C. Wainwright reiterates Buy on Intensity Therapeutics stock By Investing.com - Investing.com Canada

Aug 19, 2026

H.C. Wainwright reiterates Buy on Intensity Therapeutics stock - Investing.com

Aug 19, 2026

Analysts Offer Insights on Healthcare Companies: Quoin Pharmaceuticals (QNRX) and Pliant Therapeutics (PLRX) - The Globe and Mail

Aug 19, 2026

Aug 18, 2026

INTS Stock Price, Quote & Chart - ChartMill

Aug 18, 2026

INTENSITY THERAPEUTICS, INC. : H.C. WAINWRIGHT RAISES TARGET PRICE TO $7 FROM $5 - Bitget

Aug 18, 2026

INTS Maintained by HC Wainwright & Co. -- Price Target Raised to $7.00 - GuruFocus

Aug 18, 2026

H.C. Wainwright Maintains Intensity Therapeutics(INTS.US) With Buy Rating, Cuts Target Price to $7 - Moomoo

Aug 18, 2026

Aug 16, 2026

Intensity Therapeutics (INTS) Dips 1% to $3.96, Trading Range Holds with Support at $3.76Zero Lag EMA - vinanet.vn

Aug 16, 2026

Aug 12, 2026

Earnings call transcript: Intensity Therapeutics misses Q2 2026 EPS as shares slip premarket - Investing.com UK

Aug 12, 2026

Intensity Therapeutics (INTS) Q2 2026 Earnings Call Transcript - aol.com

Aug 12, 2026

Aug 11, 2026

Intensity Therapeutics, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance

Aug 11, 2026

A. G. P. Maintains Intensity Therapeutics(INTS.US) With Buy Rating, Cuts Target Price to $15 - Moomoo

Aug 11, 2026

Intensity Therapeutics Warns of Substantial Doubt - minichart.com.sg

Aug 11, 2026

Intensity Therapeutics Q2 Results: EPS loss narrows 67% YoY - scanx.trade

Aug 11, 2026

INTS: Q2 2026 saw higher R&D spend, resumed trial enrollment, and strong early TNBC efficacy data - TradingView

Aug 11, 2026

Transcript : Intensity Therapeutics, Inc., Q2 2026 Earnings Call, Aug 11, 2026 - marketscreener.com

Aug 11, 2026

Form 8K Intensity Therapeutics Inc For: 11 August By Investing.com - Investing.com Australia

Aug 11, 2026

INTS: Net loss rose 19% to $3M as clinical trials resumed, with $9.5M cash and $30M more needed for completion - TradingView

Aug 11, 2026

Intensity Therapeutics (INTS) Advances Clinical Trials Amidst Ch - GuruFocus

Aug 11, 2026

Intensity Therapeutics Reports $3.0 Million Q2 Net Loss - Quiver Quantitative

Aug 11, 2026

Intensity Therapeutics reports Q2 2026 net loss of $3.0M, cash $9.5M; resumes select trial enrollment - TradingView

Aug 11, 2026

Intensity Therapeutics Q2 net loss widens as R&D costs rise - TradingView

Aug 11, 2026

INTS: Resumed clinical trial enrollment and raised capital, with improved early TNBC study results - TradingView

Aug 11, 2026

BRIEF-Intensity Therapeutics Q2 Operating Income USD -3.084 Million - TradingView

Aug 11, 2026

Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - PR Newswire

Aug 11, 2026

INTENSITY THERAPEUTICS, INC. Q2 2026: Net income $(3.0M), EPS $(1.11) — 10-Q Summary - TradingView

Aug 11, 2026

Aug 10, 2026

INTS Q2'26 Earnings: EPS estimate is (0.87) USD - TradingView

Aug 10, 2026

Aug 09, 2026

BRIEF-Intensity Therapeutics Q1 Operating Income USD -2.526 Million - TradingView

Aug 09, 2026

Aug 07, 2026

Intensity Therapeutics (INTS.US) will release its earnings report on August 11. - Moomoo

Aug 07, 2026